<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39273444</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>17</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9498</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms25179498</ELocationID><Abstract><AbstractText>The ongoing COVID-19 pandemic, caused by SARS-CoV-2, continues to pose significant global health challenges. The results demonstrated that GB-2 at 200 μg/mL effectively increased the population of 293T-ACE2 cells with low RBD binding for both SARS-CoV-2 Omicron EG.5.1 and HV.1 variants by dual-color flow cytometry, indicating its ability to inhibit virus attachment. Further investigation revealed that (+)-catechin at 25 and 50 μg/mL did not significantly alter the ACE2-RBD interaction for the EG.5.1 variant. In contrast, theaflavin showed inhibitory effects at both 25 and 50 μg/mL for EG.5.1, while only the higher concentration was effective for HV.1. Notably, theaflavin 3-gallate exhibited a potent inhibition of ACE2-RBD binding for both variants at both concentrations tested. Molecular docking studies provided insight into the binding mechanisms of theaflavin and theaflavin 3-gallate with the RBD of EG.5.1 and HV.1 variants. Both compounds showed favorable docking scores, with theaflavin 3-gallate demonstrating slightly lower scores (-8 kcal/mol) compared to theaflavin (-7 kcal/mol) for both variants. These results suggest stable interactions between the compounds and key residues in the RBD, potentially explaining their inhibitory effects on virus attachment. In conclusion, GB-2, theaflavin, and theaflavin 3-gallate demonstrate significant potential as inhibitors of the ACE2-RBD interaction in Omicron variants, highlighting their therapeutic promise against COVID-19. However, these findings are primarily based on computational and in vitro studies, necessitating further in vivo research and clinical trials to confirm their efficacy and safety in humans.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Chung-Kuang</ForeName><Initials>CK</Initials><Identifier Source="ORCID">0000-0002-3688-5002</Identifier><AffiliationInfo><Affiliation>Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lung</LastName><ForeName>Jrhau</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2100-3713</Identifier><AffiliationInfo><Affiliation>Department of Research and Development, Chiayi Chang Gung Memorial Hospital, Chiayi Branch, Putzu 613, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shu</LastName><ForeName>Li-Hsin</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hung-Te</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yu-Huei</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yu-Shih</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yao-Hsu</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chinese medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital, Chiayi 613, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yu-Heng</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Institute of Communications Engineering, The National Yang Ming Chiao Tung University, Hsinchu City 30010, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Ching-Yuan</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chinese medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOST 112-2320-B-182-022-MY3</GrantID><Agency>Ministry of Science and Technology (TW)</Agency><Country /></Grant><Grant><GrantID>CMRPG6N0122</GrantID><Agency>Chang Gung Memorial Hospital (Chiayi)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8R1V1STN48</RegistryNumber><NameOfSubstance UI="D002392">Catechin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044946">Biflavonoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>1IA46M0D13</RegistryNumber><NameOfSubstance UI="C056068">theaflavin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>31629-79-5</RegistryNumber><NameOfSubstance UI="C088983">theaflavine gallate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>632XD903SP</RegistryNumber><NameOfSubstance UI="D005707">Gallic Acid</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002392" MajorTopicYN="Y">Catechin</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044946" MajorTopicYN="Y">Biflavonoids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="Y">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053585" MajorTopicYN="N">Virus Attachment</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005707" MajorTopicYN="N">Gallic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GB-2</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">omicron variants</Keyword><Keyword MajorTopicYN="N">spike protein</Keyword><Keyword MajorTopicYN="N">theaflavin</Keyword><Keyword MajorTopicYN="N">theaflavin 3-gallate</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39273444</ArticleId><ArticleId IdType="pmc">PMC11394907</ArticleId><ArticleId IdType="doi">10.3390/ijms25179498</ArticleId><ArticleId IdType="pii">ijms25179498</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  COVID-19 Epidemiological Update.  [(accessed on 17 May 2024)].  Available online:  https://www.who.int/publications/m/item/covid-19-epidemiological-update-edition-167.</Citation></Reference><Reference><Citation>Lamers M.M., Haagmans B.L. SARS-CoV-2 pathogenesis. Nat. Rev. Microbiol. 2022;20:270–284. doi: 10.1038/s41579-022-00713-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00713-0</ArticleId><ArticleId IdType="pubmed">35354968</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M., Kuppalli K., Kindrachuk J., Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862. doi: 10.1136/bmj.m3862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3862</ArticleId><ArticleId IdType="pubmed">33097561</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Zhang H.X., Zhang J. Investigation on the interaction mechanism of different SARS-CoV-2 spike variants with hACE2: Insights from molecular dynamics simulations. Phys. Chem. Chem. Phys. 2023;25:2304–2319. doi: 10.1039/D2CP04349A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2CP04349A</ArticleId><ArticleId IdType="pubmed">36597957</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi H., Wang J., Wang J., Lu Y., Zhang Y., Peng R., Lu J., Chen Z. The Emergence and Spread of Novel SARS-CoV-2 Variants. Front. Public Health. 2021;9:696664. doi: 10.3389/fpubh.2021.696664.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.696664</ArticleId><ArticleId IdType="pmc">PMC8364952</ArticleId><ArticleId IdType="pubmed">34409009</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C., Sharma A.R., Bhattacharya M., Lee S.S. A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. Front. Immunol. 2022;13:801522. doi: 10.3389/fimmu.2022.801522.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.801522</ArticleId><ArticleId IdType="pmc">PMC8863680</ArticleId><ArticleId IdType="pubmed">35222380</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberiyan M., Karimi E., Khademi Z., Movahhed P., Safi A., Mehri-Ghahfarrokhi A. SARS-CoV-2: Phenotype, genotype, and characterization of different variants. Cell. Mol. Biol. Lett. 2022;27:50. doi: 10.1186/s11658-022-00352-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11658-022-00352-6</ArticleId><ArticleId IdType="pmc">PMC9204680</ArticleId><ArticleId IdType="pubmed">35715738</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z., Zhu Y., Chu M. Role of COVID-19 Vaccines in SARS-CoV-2 Variants. Front. Immunol. 2022;13:898192. doi: 10.3389/fimmu.2022.898192.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.898192</ArticleId><ArticleId IdType="pmc">PMC9165056</ArticleId><ArticleId IdType="pubmed">35669787</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhan W., Liu J., Wang Y., Zhang X., Zhang M., Han L., Ma Y., Lu L., Wen Y., et al. A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding. Cell Res. 2022;32:862–865. doi: 10.1038/s41422-022-00684-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-022-00684-0</ArticleId><ArticleId IdType="pmc">PMC9244094</ArticleId><ArticleId IdType="pubmed">35768499</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah M., Woo H.G. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies. Front. Immunol. 2021;12:830527. doi: 10.3389/fimmu.2021.830527.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.830527</ArticleId><ArticleId IdType="pmc">PMC8819067</ArticleId><ArticleId IdType="pubmed">35140714</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer O. COVID-19: Infections climb globally as EG.5 variant gains ground. BMJ. 2023;382:1900. doi: 10.1136/bmj.p1900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.p1900</ArticleId><ArticleId IdType="pubmed">37586736</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamble P., Daulatabad V., Singhal A., Ahmed Z.S., Choubey A., Bhargava S., John N.A. JN.1 variant in enduring COVID-19 pandemic: Is it a variety of interest (VoI) or variety of concern (VoC)? Horm. Mol. Biol. Clin. Investig. 2024;45:49–53. doi: 10.1515/hmbci-2023-0088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/hmbci-2023-0088</ArticleId><ArticleId IdType="pubmed">38622986</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Guo Y., Bowen A., Mellis I.A., Valdez R., Gherasim C., Gordon A., Liu L., Ho D.D. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe. 2024;32:315–321.e313. doi: 10.1016/j.chom.2024.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2024.01.014</ArticleId><ArticleId IdType="pmc">PMC10948033</ArticleId><ArticleId IdType="pubmed">38377995</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S., McGhee N., Whatley J.L., Essink B., Brosz A., Tomassini J.E., Girard B., Edwards D.K., Wu K., Nasir A., et al. Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines. J. Infect. Dis. 2024;230:e279–e286. doi: 10.1093/infdis/jiae067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiae067</ArticleId><ArticleId IdType="pmc">PMC11326827</ArticleId><ArticleId IdType="pubmed">38349280</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.Y., Yang Y.H., Lin Y.S., Shu L.H., Cheng Y.C., Liu H.T., Lin Y.Y., Lee I.Y., Shih W.T., Yang P.R., et al. The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solution. Heliyon. 2023;9:e17701. doi: 10.1016/j.heliyon.2023.e17701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e17701</ArticleId><ArticleId IdType="pmc">PMC10359827</ArticleId><ArticleId IdType="pubmed">37483781</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.Y., Yang Y.H., Lin Y.S., Shu L.H., Liu H.T., Lu C.K., Wu Y.H., Wu Y.H. The Effect and Mechanism of Astragalus Polysaccharides on T Cells and Macrophages in Inhibiting Prostate Cancer. Biomed. J. 2024:100741. doi: 10.1016/j.bj.2024.100741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2024.100741</ArticleId><ArticleId IdType="pubmed">38677490</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.Y., Lin Y.S., Yang Y.H., Shu L.H., Cheng Y.C., Liu H.T. GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies. Biomed. Pharmacother. 2020;132:110816. doi: 10.1016/j.biopha.2020.110816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110816</ArticleId><ArticleId IdType="pmc">PMC7547400</ArticleId><ArticleId IdType="pubmed">33049583</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury P., Sahuc M.E., Rouille Y., Riviere C., Bonneau N., Vandeputte A., Brodin P., Goswami M., Bandyopadhyay T., Dubuisson J., et al. Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. PLoS ONE. 2018;13:e0198226. doi: 10.1371/journal.pone.0198226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0198226</ArticleId><ArticleId IdType="pmc">PMC6261387</ArticleId><ArticleId IdType="pubmed">30485282</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y.C., Chen Y.C., Lin Y.L., Lin-Shiau S.Y., Ho C.T., Lin J.K. Suppression of extracellular signals and cell proliferation by the black tea polyphenol, theaflavin-3,3’-digallate. Carcinogenesis. 1999;20:733–736. doi: 10.1093/carcin/20.4.733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/20.4.733</ArticleId><ArticleId IdType="pubmed">10223207</ArticleId></ArticleIdList></Reference><Reference><Citation>Sil D., Gautam S., Saxena S., Joshi S., Kumar D., Mehta A., Jindal P., Sharma S., Pandey P., Diksha, et al. Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact. Curr. Drug Targets. 2024;25:517–525. doi: 10.2174/0113894501296586240430061915.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0113894501296586240430061915</ArticleId><ArticleId IdType="pubmed">38726782</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai M.S., Yang Y.H., Lin Y.S., Chang G.H., Hsu C.M., Yeh R.A., Shu L.H., Cheng Y.C., Liu H.T., Wu Y.H., et al. GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2. Biomed. Pharmacother. 2021;142:112011. doi: 10.1016/j.biopha.2021.112011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112011</ArticleId><ArticleId IdType="pmc">PMC8339502</ArticleId><ArticleId IdType="pubmed">34388530</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K.K., Dorosky D., Sharma P., Abbasi S.A., Dye J.M., Kranz D.M., Herbert A.S., Procko E. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science. 2020;369:1261–1265. doi: 10.1126/science.abc0870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc0870</ArticleId><ArticleId IdType="pmc">PMC7574912</ArticleId><ArticleId IdType="pubmed">32753553</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyngse F.P., Kirkeby C.T., Denwood M., Christiansen L.E., Molbak K., Moller C.H., Skov R.L., Krause T.G., Rasmussen M., Sieber R.N., et al. Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark. Nat. Commun. 2022;13:5760. doi: 10.1038/s41467-022-33498-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33498-0</ArticleId><ArticleId IdType="pmc">PMC9524324</ArticleId><ArticleId IdType="pubmed">36180438</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., He Y., Liu H., Shang Y., Guo G. Potential immune evasion of the severe acute respiratory syndrome coronavirus 2 Omicron variants. Front. Immunol. 2024;15:1339660. doi: 10.3389/fimmu.2024.1339660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1339660</ArticleId><ArticleId IdType="pmc">PMC10924305</ArticleId><ArticleId IdType="pubmed">38464527</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanai T. Quantitative in silico analysis of SARS-CoV-2 S-RBD omicron mutant transmissibility. Talanta. 2022;240:123206. doi: 10.1016/j.talanta.2022.123206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.talanta.2022.123206</ArticleId><ArticleId IdType="pmc">PMC8739820</ArticleId><ArticleId IdType="pubmed">35026638</ArticleId></ArticleIdList></Reference><Reference><Citation>Alanzi A.R., Parvez M.K., Al-Dosari M.S. Structure-based virtual identification of natural inhibitors of SARS-CoV-2 and its Delta and Omicron variant proteins. Future Virol. 2023;18:421–438. doi: 10.2217/fvl-2022-0184.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2022-0184</ArticleId><ArticleId IdType="pmc">PMC10241455</ArticleId><ArticleId IdType="pubmed">38051986</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel C.N., Jani S.P., Prasanth Kumar S., Modi K.M., Kumar Y. Computational investigation of natural compounds as potential main protease (M(pro)) inhibitors for SARS-CoV-2 virus. Comput. Biol. Med. 2022;151:106318. doi: 10.1016/j.compbiomed.2022.106318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2022.106318</ArticleId><ArticleId IdType="pmc">PMC9673090</ArticleId><ArticleId IdType="pubmed">36423529</ArticleId></ArticleIdList></Reference><Reference><Citation>Goc A., Rath M., Niedzwiecki A. Composition of naturally occurring compounds decreases activity of Omicron and SARS-CoV-2 RdRp complex. Eur. J. Microbiol. Immunol. (Bp) 2022;12:39–45. doi: 10.1556/1886.2022.00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1556/1886.2022.00009</ArticleId><ArticleId IdType="pmc">PMC9630930</ArticleId><ArticleId IdType="pubmed">35895480</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma J., Rath P.P., Gourinath S., Subbarao N. Identification of potential novel inhibitors against the SARS-CoV-2 spike protein: Targeting RBD and ACE2 interaction. J. Biomol. Struct. Dyn. 2023:1–11. doi: 10.1080/07391102.2023.2291161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2023.2291161</ArticleId><ArticleId IdType="pubmed">38063058</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan M., Bhardwaj V.K., Kumar A., Kumar V., Kumar P., Enayathullah M.G., Thomas J., George J., Kumar B.K., Purohit R., et al. Theaflavin 3-gallate inhibits the main protease (M(pro)) of SARS-CoV-2 and reduces its count in vitro. Sci. Rep. 2022;12:13146. doi: 10.1038/s41598-022-17558-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-17558-5</ArticleId><ArticleId IdType="pmc">PMC9338964</ArticleId><ArticleId IdType="pubmed">35908093</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A., Kanwar M., Maiti S. Theaflavin-3’-O-gallate a Black-tea Constituent Blocked SARS-CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir. Drug Res. 2021;71:462–472. doi: 10.1055/a-1467-5828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1467-5828</ArticleId><ArticleId IdType="pubmed">34517419</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogoi M., Borkotoky M., Borchetia S., Chowdhury P., Mahanta S., Barooah A.K. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): A virtual screening and molecular dynamic simulation study. J. Biomol. Struct. Dyn. 2022;40:7143–7166. doi: 10.1080/07391102.2021.1897679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2021.1897679</ArticleId><ArticleId IdType="pubmed">33715595</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.Y., Lin Y.S., Yang Y.H., Shu L.H., Cheng Y.C., Liu H.T. Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2. Front. Pharmacol. 2020;11:584158. doi: 10.3389/fphar.2020.584158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.584158</ArticleId><ArticleId IdType="pmc">PMC7773841</ArticleId><ArticleId IdType="pubmed">33390952</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai M.S., Shih W.T., Yang Y.H., Lin Y.S., Chang G.H., Hsu C.M., Yeh R.A., Shu L.H., Cheng Y.C., Liu H.T., et al. Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations. Biomed. Pharmacother. 2022;149:112802. doi: 10.1016/j.biopha.2022.112802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.112802</ArticleId><ArticleId IdType="pmc">PMC8906167</ArticleId><ArticleId IdType="pubmed">35279013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong H.L.K.-S.L.M.-H. idock: A multithreaded virtual screening tool for flexible ligand docking; Proceedings of the 2012 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB); San Diego, CA, USA. 9–12 May 2012;</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/CIBCB.2012.6217214</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>